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Henoch Scho¨nlein Purpura (HSP) is a common disease in
children, usually associated with a good prognosis. In adults
there are no prospective studies concerning its prognosis or
treatment, especially in cases of severe visceral involvement.
Here we compared steroid therapy without or with
cyclophosphamide co-treatment in adults with severe HSP
in a 12-month, multi-center, prospective, open-label trial
that treated 54 adults with biopsy-proven HSP including
proliferative glomerulonephritis and severe visceral
manifestations. All received steroids; however, 25 were
randomized to also receive cyclophosphamide. The primary
endpoint that occurred in three patients in each group was
complete disease remission defined as zero on the
Birmingham Vasculitis Activity Score with no persistent or
new clinical and/or biological vasculitis at 6 months. No
patient had active visceral involvement. The secondary
endpoints were renal outcome, deaths, and adverse events at
12 months. Renal function, proteinuria, safety data, incidence
of diabetes, and severe infections were similar between the
two groups. At the last follow-up, renal function remained
stable. The small population size of our study does not
permit definitive conclusions; however, we suggest that
treatment of adults with severe HSP by adding
cyclophosphamide provides no benefit compared with
steroids alone.
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Henoch Scho¨nlein Purpura (HSP) is the most frequent
vasculitis in childhood. HSP occurs less frequently in adults,
but is usually more severe than that in children.1,2
Gastrointestinal and pulmonary involvement can be life-
threatening, and HSP nephritis with severe endo- and/or
extra-capillary proliferation on biopsy can progress to end-
stage renal disease in up to 30% of patients during long-term
follow-up.3,4
Management of HSP remains controversial. In children,
various treatment regimens have been proposed in cases of
severe digestive involvement or nephritis, including cortico-
steroids, azathioprine, cyclophosphamide, cyclosporine, myco-
phenolate mofetil, and recently, rituximab.5–9 Results have
been conflicting. In adults, however, no randomized study
has been undertaken to evaluate the efficacy of any treatment
modality.
The aim of this prospective, randomized study was to
compare the efficacy and safety of steroids alone or in
combination with pulse cyclophosphamide for the treatment
of severe adult HSP.
RESULTS
Fifty-four patients were recruited in 31 centers in France
between September 2002 and September 2006, and were
randomized to receive steroids alone (CS) (n¼ 29) or
steroids and cyclophosphamide (CYS) (n¼ 25) (Figure 1).
Long-term follow-up continued to 1 April 2009, with follow-
up data being obtained for 20 patients in the CS group
(including two patients evaluated before death) and 20
patients in the CSþCYC group (data were missing for one
patient in addition to those who were deceased and lost to
follow-up), with a median follow-up of 60.9 months (first
quartile to third quartile (Q1–Q3): 47.4–69.7 months) and
59.8 months (Q1–Q3: 49.2–68.0 months), respectively.
Clinical findings at baseline
The demographic and baseline disease characteristics are
presented in Table 1. Age at study entry ranged from 18 to 84
years. The two treatment groups were well-balanced except
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Figure 1 |Patient disposition. All patients received the allocated treatment. Patients shown as ‘not evaluated’ did not attend the relevant
study visit. The last follow-up took place at a median of 61 months in the CS group and at 60 months in the CSþCYC group.
Table 1 | Demographic, clinical, and biological characteristics at baseline
Steroids Steroids+cyclophosphamide P-value
n 29 25
Sex, male, n (%) 17 (58.6%) 17 (68.0%) 0.66
Mean (s.d.) age (years) 60.7 (11.0) 52.8 (18.5) 0.01
Recent history of infection, n (%) 12 (41.4%) 11 (44.0%)
Comorbidities
Hypertension, n (%) 15 (51.7%) 6 (24.0%) 0.04
Diabetes, n (%) 7 (24.1%) 3 (12.0%) 0.31
Physical examination
Blood pressure (mmHg), mean 134/77 130/74
Mean (s.d.) weight (kg) 79.2 (17.4) 72.0 (13.8)
Skin lesions 28 (96.6%) 24 (96.0%)
Type: purpura 26/28 (92.9%) 23/24 (95.8%)
Necrosis: bullous, n (%) 11/28 (39.3%) 8/24 (33.3%)
Gastrointestinal involvement, n (%) 16 (55.2%) 13 (52%)
Moderate abdominal pain, n (%) 8 (27.6%) 5 (20.8%)
Severe involvement, n (%) 8 (27.6%) 7 (29.2%)
Joint manifestation, n (%) 16 (55.2%) 16 (64.0%) 0.70
Other organ involvement, n (%) 2 (7.1%) 3 (13.0%) 0.90
Biological tests
CRP (mg/l), median (range) 28 (3–193) 28 (0–222)
Albumin (g/l), median (range) 28 (13–37) 30 (13–48)
Creatinine (mmol/l), median (range) 110 (53–668) 88 (61–903) 0.22
eGFR (ml/min), median (range) 60 (10–125) 76 (9–132) 0.36
eGFRo60ml/min, n (%) 14 (48.3%) 9 (36.0%)
Proteinuria (g/24 h), median (range) 3.2 (0; 21) 3.6 (0; 12)
Proteinuria X1 g/day, n (%) 21 (72.4%) 22 (88%)
Hematuria X10 RBC/mm3, n (%) 23 (88.5%) 22 (95.7%)
Renal biopsies 24 24
Glomerular score (class), n (%)
Mesangiopathic GN (1) 1 (4.2%) 0 (0%)
Focal and segmental GN (2) 4 (16.7%) 4 (16.7%)
Endocapillary proliferative GN (3) 10 (41.7%) 13 (54.2%)
Endo/extra-capillary proliferative GN (4) 9 (37.5%) 7 (29.2%)
Global glomerular sclerosis, median (range) 1 (0–4) 1 (0–3)
Interstitial fibrosis (%), median (range) 13 (0–40) 0 (0–40)
None–mild (o25%), n 16 21 0.17
Moderate (25–50%), n 8 3
Severe (450%), n 0 0
Vascular disease, n (%) 17 (70.8%) 14 (58.3%)
Skin biopsies 23 21
Leukocytoclastic vasculitis, n (%) 23 (100.0%) 18 (85.7%)
Abbreviations: CRP, C-reactive protein; eGFR, estimated renal function; GN, glomerulonephritis; n, number of patients.
The two treatment groups were well-balanced except, due to the lower number of recruited patients, for age and hypertension.
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for age, hypertension, and disease activity (assessed by
Birmingham Vasculitis Activity Score (BVAS)), due to the
low number of patients recruited. Indeed, the patients in the
CSþCYC group were younger, less hypertensive, had lower
vasculitis disease activity, and better renal function. The most
frequent clinical manifestation in all HSP patients was
purpura, which was predominantly observed on the lower
limbs. Purpura was necrotic or bullous in 19/52 patients
(36.5%), with similar incidence in each cohort. Joint
manifestations were present in 59.3% of the patients
(32/54), including 16 patients in each group (Table 1). Fever
and/or alteration of clinical status were observed in 50% of
the patients at baseline (26/54): 58.3% (17/29) in the CS
group versus 11/25 (44.0%) in the CSþCYS group.
Gastrointestinal involvement was present in 29 patients
(53.7%) overall, and each of these patients experienced
abdominal pain. Three patients in the CS group and two in
the CSþCYC group had gastrointestinal hemorrhage. Bowel
ischemia was present in five CS patients and eight CSþCYC
patients. One CS patient and two CS patients had severe
gastrointestinal involvement without nephritis.
Renal findings at baseline
At baseline, as shown in Table 1, median creatinine was
110 mmol/l (range 53–668 mmol/l) in the CS group and
88 mmol/l (61–903 mmol/l) in the CSþCYC cohort. The
estimated glomerular filtration rate (eGFR) (Cockroft–Gault)
was 60 ml/min (10–225 ml/min) versus 76 ml/min (9–132
ml/min), respectively. Fourteen patients (48%) in the CS
group and nine (36%) in the CSþCYC group had
eGFRo60 ml/min at baseline, with two CS patients and
three CSþCYC patients requiring dialysis.
A similar proportion of patients in each group had
proteinuria 40.2 g/day (CS, 27/29 (93%); CSþCYC, 24/25
(96%)). Proteinuria X1 g/day was present in 21/29 CS
patients (72%) and 22/25 CSþCYC patients (88%). Of note,
10/29 (34%) CS patients versus 11/24 (46%) CSþCYC
patients presented with nephrotic syndrome.
Hypertension was present in 15/29 (52%) CS patients and
6/25 (24%) CSþCYC patients. Of these, 19 patients received
renin–angiotensin system blockers (CS, 11; CSþCYC, 8).
Renal biopsy results at baseline were available for 24
patients in each group. The two groups were well-matched
with respect to histological findings, exhibiting a similar
degree of glomerulosclerosis, tubular atrophy, interstitial
fibrosis, and vascular disease. Diffuse endocapillary prolif-
erative glomerulonephritis (GN) (class-3 and 4) was observed
on 79.2% of the biopsies from the CS group and 83.4% of the
biopsies from the CSþCYC group.
Primary endpoint
As shown in Table 2a, the BVAS improved substantially in
both the groups from day 0 (CS, median 28 (range 12–48);
CSþCYC, 20 (7–45); P¼ 0.02) to month 6 (M6) (CS, 12
(0–45); CSþCYC, 9 (0–28); P¼ 0.41). The median decrease
in the BVAS from day 0 to M6 was 17 (range 26; 7) in
the CS group versus 12 (20; 6) in the CSþCYC group
(P¼ 0.14). The primary endpoint, a BVAS of zero with no
persisting or new clinical and/or biological vasculitis activity
at M6, occurred in three patients in each group (CS, 3/29
Table 2 | Clinical and biological endpoints
Steroids Steroids+cyclophosphamide P-value
(a) Primary endpointsa
n 29 25
BVAS
Score at day 0, median (range) 28 (12–48) 20 (7–45) 0.02
BVAS score=0 at month 6, n 3 (10) 3 (12) 1.00
Score at month 6, median (range) 12 (0–45) 9 (0–28) 0.41
Change from day 0 to month 6, median (range) 17 (38; 1) 12 (33; 9) 0.14
Improvement (o1) 26 22
Unchanged (1–1) 3 2
Worsening (41) 0 1
(b) Secondary endpointsb
HSP nephritis at month 12 29 25
Blood pressure 4125/75mmHg, n (%); n=19/16 15 (79%) 13 (81%) 0.99
Creatinine (mmol/l), median (range); n=19/16 98 (79–123) 93 (74–134) 0.81
eGFR (ml/min), median (range); n=19/15 70 (17–123) 77 (18–115) 0.52
eGFRo60ml/min, n (%) n=19/15 8 (42%) 5 (33%) 1.00
Proteinuria (g/day), median (range); n=15/15 0.3 (0–3.6) 0.6 (0–2.0) 0.76
Proteinuria X1 g/day, n (%) 4 (27%) 3 (20%)
Hematuria X10 RBC/mm3, n (%); n=11/12 3 (27%) 5 (42%) 0.67
RAS blockers, n (%); n=19/17 14 (74%) 12 (71%) 1.00
Renal function improvement 450%, n (%); n=19/16 4 (21%) 1 (6%) 0.35
End-stage renal disease, n 1 1
Abbreviations: BVAS, Birmingham Vasculitis Activity Score; eGFR, estimated renal function; n, number of patients; RAS, renin–angiotensin system; RBC, red blood cells.
aDisease activity at baseline, as assessed by the BVAS, was lower in the CS+CYC group. At month 6, no patient showed active visceral involvement.
bHSP nephritis. At month 12, renal function and proteinuria were not different in both the groups.
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(10.3%); CSþCYC, 3/25 (12.0%); P¼ 1.00). Logistic regres-
sion modeling confirmed the absence of difference in the
incidence of the primary endpoint between the treatment
groups after adjustment for age, BVAS, and hypertension at
study entry.
Some patients still experienced clinical manifestations at
M6, but without any visceral involvement. Six patients in the
CSþCYC group presented with skin purpura at M6,
including one case of necrotic and bullous purpura. Other
manifestations at M6 included persisting arthralgia in three
patients and minor abdominal pain in one patient, all withi
the CSþCYC group. At the end of the follow-up no patients
showed any extra-renal manifestation.
Renal outcome
As shown in Table 2b, renal outcome was similar between the
two groups even after stratification according to baseline
parameters, including histopathological criteria.
Renal function improved to a similar extent in both the
groups by month 12 (M12), with eGFR increasing by 450%
in 4/19 CS patients (21%) and 1/16 (6%) CSþCYC patients
(Figure 2a). By M12, 8/19 (42%) patients in the CS group
versus 6/16 (38%) patients in the CSþCYC group had
eGFRo60 ml/min (P¼ 0.33). One patient in each group
reached end-stage renal disease, with a delay of 8 and 12
weeks, respectively. Even though the number of patients
exceeding 48 months of follow-up was relatively small, it
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Figure 2 |Renal outcome. (a) eGFR (Cockcroft–Gault) and (b) daily proteinuria (g/day) in patients receiving steroids alone (CS, open boxes)
or steroids and cyclophosphamide (CSþCYC, filled boxes) from day 0 (D0) until the last follow-up (LF).
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should be emphasized that renal function remains stable at
the last follow-up. At the last follow-up, median serum
creatinine was 103 mmol/l (range: 51–390 mmol/l) in the CS
arm versus 90 mmol/l (range: 50–219 mmol/l) in the CSþCYC
arm (P¼ 0.32), and median eGFR was 69 ml/min (range:
27–120 ml/min) versus 72 ml/min (range: 28–150 ml/min),
respectively (P¼ 0.55).
At 1 year, only 27% (4/15) of the CS patients and 20%
(3/15) of the CSþCYC patients had proteinuria X1 g/day,
and no patient had nephrotic syndrome. At the end of the
follow-up, median proteinuria was 0.2 g/day in both the
groups (P¼ 0.89; Figure 2b).
By the end of the 1-year study, seven patients had became
hypertensive for the first time (CS 2, CSþCYC 5), and at
1 year 14/19 (74%) CS patients and 12/17 (71%) CSþCYC
patients were receiving renin–angiotensin system blockers.
Safety
At M12, patient survival was 87% (95% confidence interval
(CI) 79–95). Overall survival was not different between the
two groups (CS group, 79% (95% CI 64–93) versus
CSþCYC group, 96% (95% CI 89–100); P¼ 0.08, log-rank
test) (Figure 3). As shown at M6 in Table 3, six CS patients
died due to hemorrhagic shock (n¼ 2), end-stage liver
disease (n¼ 2), and unknown causes, which was not related
to the disease or its treatment (n¼ 2). In the CSþCYC
group, one patient died of myocardial infarction, 6 days after
study entry. The investigators did not relate any death either
to HSP activity or to adverse events of the study drugs. At the
end of the follow-up, the number of deaths did not differ
significantly between the two groups (CS, 9; CSþCYC, 3;
hazards ratio, 3.0, 95% CI 0.8–11.3; P¼ 0.10). Adjusted to the
treatment arm by multivariable analysis, the BVAS at
inclusion was the only parameter to show a statistically
significant relationship with patient survival (hazards ratio,
2.4 for an increase of 10 BVAS points, 95% CI 1.4–4.5;
P¼ 0.003).
Ten patients in the CS group experienced infections, one
of whom required hospital admission. Seven patients in the
CSþCYC group developed infections, none requiring
hospital admission. Newly diagnosed diabetes or deteriora-
tion of pre-existing diabetes was reported in seven patients in
the CS arm and six in the CSþCYC arm. Allocated
treatment was discontinued before the end of the study for
three patients of the CS group (lack of efficacy (two patients)
and lost to follow-up) and four patients in the CSþCYC
group (pregnancy, bladder tumor, lack of efficacy, and lost to
follow-up).
DISCUSSION
Although several studies have investigated the treatment of
HSP nephritis in children, no trial has previously been
undertaken in adults. In this prospective, randomized trial we
observed no benefit from addition of cyclophosphamide to
steroid therapy for adult patients with severe HSP. It is
unlikely that variations in the baseline characteristics would
explain the lack of difference between the two treatment
groups, as the result was unchanged after adjustment by
logistic regression modeling. Indeed, only 54 patients could
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Figure 3 |Kaplan–Meier curves comparing patients receiving
steroids alone (CS) or associated with cyclophosphamide
(CSþCYC): survival from randomization to the end of follow-
up. Adjusted to treatment arm by multivariable analysis, BVAS at
inclusion was the only parameter to show a statistically significant
relationship with patient survival (hazards ratio, 2.4 for an increase
of 10 BVAS points, 95% CI 1.4–4.5; P¼ 0.003).
Table 3 | Number of patients experiencing adverse events
during the 12-month study
Steroids
Steroids+
cyclophosphamide
n 29 25
Adverse events
Infection 10 7
Urinary tract 4 2
Necrotizing fasciitis 1 1
Zona zoster 0 1
Mycobacterium tuberculosis 1 0
Bronchitis 4 3
Diabetesa 7 6
Depression anxiety 2 2
Insomnia 3 0
Alopecia 1 1
Acne vulgaris/atrophia striata 0 1/1
Vertebral fracture 1
Deaths 6 1
Hemorrhagic shock 2
Myocardial infarct 1
End-stage liver disease 2
Unknown 2
All tests are non-statistically significant at level 5%.
aNewly diagnosed or deterioration of pre-existing diabetes.
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have been enrolled in the scheduled inclusion period. The
stratification per center in combination with the small
contribution of some centers resulted in this skewed
distribution.
Our finding is in accordance with data from ‘pediatric
studies. A systematic review of 10 randomized, controlled
trials in children concluded that of the few available
therapies, only short-term prednisone improved renal out-
come in pediatric HSP.5 Some authors have even suggested
that steroids, and more importantly, immunosuppressive
drugs, offer no advantage in children with HSP nephritis.6 A
recent meta-analysis reported that early corticosteroid
treatment in children reduces the risk that chronic renal
disease will develop, although the robustness of their
conclusions was limited by the small number of studies and
patients, variable dosing regiments, and the degree of HSP
severity.7 Despite the lack of reliable evidence, we felt it to be
unethical to include a placebo arm in this study.
Our findings also provide a prospective description of the
course of severe HSP in adults. In our population, which was
comparable to previously reported cohorts with regard to
renal and extra-renal manifestations,1,2,4,10–15 the short- and
medium-term prognosis was good regardless of the treatment
group. Both BVAS and proteinuria improved dramatically
during the 1-year study regardless of the treatment group,
and renal function remained stable after a median of B5
years’ follow-up. At the end of the follow-up no patient
experienced extra-renal manifestation. Our patients can be
regarded as having a positive outcome despite severe clinical
features, as significant proteinuria (41 g/day) and renal
impairment were absent during follow-up, both of which are
closely predictive of end-stage renal disease.11–14 One possible
explanation for this positive outcome is the use of
renin–angiotensin system blockers in nearly all patients. A
number of studies have shown a renoprotective effect for
angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers in IgA nephropathy.16–18
The BVAS reached zero (primary endpoint) in a very few
number of patients, equally in both the groups. Of note,
persisting microscopic hematuria, which is frequent in HSP
nephritis and usually not considered as worse prognosis,
counts 8 points in the BVAS score and accounts for the high
score measured at 6 months in our population. At 6 months
the patients showed no severe HSP manifestation, stable renal
function, and proteinuria less than 1 g/day. However, more
than half of them had a persisting microscopic hematuria.
The extra-renal manifestations were then moderate, consist-
ing of limited skin purpura on the legs in six patients (one
only with necrotic lesions) and moderate arthralgia or
abdominal pain in four patients. We speculate that the BVAS
may not be optimal to evaluate HSP vasculitis activity.
However, no score is currently available to quantify the
activity in this specific vasculitis. Further study should define
a new modified BVAS, suitable for HSP vasculitis.
No severe adverse events were reported in either group
and no deaths were considered by the investigators to be
related to HSP activity or to treatment-related adverse events.
However, it was notable that the BVAS at baseline, adjusted to
the treatment group, was the only factor, which showed a
significant relationship with risk of death. The difference in
the number of deaths between the two treatment groups
could be attributed to the differences in the baseline
characteristics (patients were significantly more severe in
the CS group). We must also emphasize that the small
number of patients included makes it difficult to draw any
clear-cut conclusions. One could argue that a treatment
group without steroid could have been included. Indeed,
during the design of this study, such a possibility was raised
but was not considered ethical by the investigators.
In summary, even though the relatively low number of
patients does not permit definitive conclusions to be drawn,
our results suggest that addition of cyclophosphamide
provides no additional benefit for adults with severe HSP
as compared with steroids alone. It is conceivable that
even steroid therapy may not be indicated in such patients,
but no treatment may be inappropriate in adult patients with
severe HSP.
METHODS
Patients
Patients aged 18–84 years were eligible to take part in the study if
they had a biopsy-proven diagnosis of HSP associated with severe
involvement of one organ. HSP diagnosis was based on the Chapell
Hill Nomenclature conference criteria,19 that is, presence of one
typical clinical manifestation (skin, gut, kidney, and/or joint) in
conjunction with biopsy evidence of leukocytoclastic vasculitis with
IgA deposition. Severe organ involvement could include renal
biopsy-proven nephritis showing diffuse endocapillary proliferation
(class-3) alone or with extra-capillary proliferation (class-4),11
severe gastrointestinal involvement (gastrointestinal hemorrhage,
ischemia, or perforation or abdominal pain persisting for more than
1 day and unresponsive to standard analgesics), pulmonary
hemorrhage, cardiac or central nervous system involvement, and/or
episcleritis.
Women of child-bearing potential were required to use one
appropriate birth control method and were excluded from the study
if they were pregnant or breastfeeding. Patients with other causes of
purpura (thrombocytopenia, bacterial, or other forms of vasculitis)
were excluded, as were patients infected by hepatitis-B and/or C
viruses or HIV. Patients were also excluded if they had received
immunosuppressants or steroids within the previous 2 weeks.
Study design
This multi-center, prospective, randomized, open-label trial inclu-
ded a 6-month treatment period with a further visit at M12. Data on
mortality, end-stage renal disease, renal function, and daily
proteinuria were collected up to the last follow-up. Randomization
was performed centrally using a computer-generated random
allocation sequence with blocks of random size. The investigators
were informed of a patient’s randomized group by telephone. As
shown on Figure 4, all patients received intravenous methylpredni-
solone (7.5 mg/kg/day) for 3 days, followed by oral prednisone
(initially 1 mg/kg/day for 1 week, and gradually tapering during the
course of the study in the following manner: to 0.4 mg/kg/day at the
end of the first month, 0.25 mg/kg/day at the end of the second
500 Kidney International (2010) 78, 495–502
or ig ina l a r t i c l e E Pillebout et al.: No benefit from cyclophosphamide in adult HSP patients
month, and stopped at the end of the sixth month). The patients
were randomly assigned to receive, in addition to steroids,
intravenous cyclophosphamide (CSþCYC) at a dose of 0.6 g/m2
on days 1 and 15, and at weeks 4, 8, 12, and 16, that is, six pulses in
total. The dose was reduced according to renal function and not
patient’s age. The maximal dose was 1200 mg.
Physicians were encouraged to achieve a blood pressure lower
than 125/75 mm Hg, favoring renin–angiotensin system blockers if
proteinuria was present.
The study protocol was approved by the ethics review committee
at each participating center and conducted according to the
Declaration of Helsinki Principles. Written informed consent was
obtained from all the patients.
Evaluation and study endpoints
Study visits took place on day 1 (the day of randomization), then
monthly to M6, with a follow-up visit at M12. On day 1, evaluation
comprised physical examination, skin biopsy of a new purpuric
lesion with histological and immunofluorescence examination, and
standard biological tests. Physical examination and biological tests,
including blood pressure, creatinine, hematuria, and daily protei-
nuria, were repeated at each subsequent visit. The BVAS was
recorded at all study visits. This score refers to new or worsening
symptoms due to vasculitis activity, with higher scores indicating
more active disease.20 All adverse events were documented
throughout the study, regardless of severity or relationship to
treatment.
Renal biopsy was performed according to local practice at each
center, usually prompted by renal failure and/or proteinuria 41
g/day. All renal biopsies were examined by two independent
pathologists masked to the treatment assignment. On immuno-
fluorescence, predominance of mesangial IgA among glomerular Ig
deposits was required. All biopsies were classified according as
follows: class-1, mesangiopathic GN; class-2, focal and segmental
GN; class-3, endocapillary proliferative GN, and class-4, endocapil-
lary and extra-capillary GN.11 The proportion of glomeruli involved
by global sclerosis was recorded. Interstitial fibrosis was scored
according to the proportion of the parenchyma involved: none–mild
(0–25%), moderate (25–50%), and severe (450%).
The primary endpoint was complete disease remission at M6,
defined as zero point on the BVAS with no persisting or new clinical
and/or biological vasculitis. The secondary end points included
renal function improvement at M12 compared with the baseline
(defined as more than 50% increase in the eGFR (Cockcroft–Gault
formula), daily proteinuria, occurrence of end-stage renal disease,
death, and adverse events (particularly diabetes mellitus and
infection)). Patient survival, end-stage renal failure, renal function,
and daily proteinuria were also assessed on the basis of the data at
the last follow-up.
Statistical analysis
The sample size calculation estimated that a population of 200
patients would have a statistical power of 80% to detect a significant
difference in the primary endpoint between the two groups, using a
two-sided test and a significance level of 5%, assuming an incidence
of 50% in the CS group and 70% in the CSþCYC group. Due to
slow recruitment only 54 patients were enrolled by the end of the
scheduled 4-year inclusion period.
All analyses were performed on the basis of the intent-to-treat
principle. The categorical variables are summarized as counts and
percentages, and continuous variables as medians (ranges) or means
(standard deviation) as appropriate. Missing BVAS results at
6 months were considered as failures in the primary endpoint
analysis and were replaced by the last obtained value for the other
54 Randomized
29 Steroids 25 Steroids +
cyclosphosphamide
Months 0-6
5 Discontinued treatment
1 Lack of efficacy
2 Patient choice
1 Not evaluated
1 Death
Months 0-6
4 Discontinued treatment
3 Deaths
1 Lack of efficacy
Month 6:
Months 0-12
Last follow-up: Last follow-up:
1 Lost to follow-up
3 Deaths (cumulative)
2 Lost to follow-up
9 Deaths (cumulative)
Months 0-12
10 Discontinued treatment 8 Discontinued treatment
6 Deaths
2 Lack of efficacy
1 Patient choice
1 Not evaluated
1 Death
1 Lack of efficacy
3 Patient choice
2 Not evaluated
1 Adverse event
29 Analyzed
Month 6:
25 Analyzed
Figure 4 | Study design. All patients received intravenous methylprednisolone for 3 days, followed by oral prednisone. The patients were
randomly assigned to receive, in addition to steroids, six pulses of intravenous cyclophosphamide.
Kidney International (2010) 78, 495–502 501
E Pillebout et al.: No benefit from cyclophosphamide in adult HSP patients o r ig ina l a r t i c l e
analyses. This replacement was chosen instead of multiple imputa-
tion because most of non-evaluated patients were deceased patients
or treatment was stopped for inefficacy. Two patients stopped the
trial at 3 months and one did not submit to the visit at M6 but was
present at month 5. Categorical data were compared by using the
w2-test or Fisher’s exact test, and continuous variables were
compared by using the Wilcoxon test or the Student’s t-test. For
the primary endpoint analysis, logistic regression modeling was used
to adjust for baseline variables. Cox regression modeling was
performed to study the relationship between treatment group,
baseline variables (age, BVAS, hypertension, diabetes, and eGFR),
and outcomes (death and end-stage renal disease) at the last follow-
up. The paucity of events meant that only two independent variables
could be included in the model, one of which was always the
treatment arm. Results are expressed as hazard ratios with 95% CIs.
All tests were two-tailed and a P-value less than 0.05 was considered
to indicate statistical significance. All statistical analyses were
performed using SAS 9.1 (SAS Inc., Cary, NC, USA) for PC.
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